KV Pharmaceutical Files for Bankruptcy, Blames FDA, Medicaid

Drug Industry Daily
A A
The FDA’s failure to enforce orphan drug marketing exclusivity for KV Pharmaceutical’s pre-term birth drug Makena, coupled with Medicaid payment restrictions, has caused the company to seek Chapter 11 protection, KV claims.

To View This Article:

Login

Subscribe To Drug Industry Daily